Week in Review • INTELLIGENCE BRIEF • April 25, 2026

TOP STORIES

Dupixent Patent Strategy Anchors Sanofi's Post-2031 Revenue Defense

Sanofi disclosed plans for a vigorous defense to extend Dupixent's U.S. exclusivity beyond March 2031, when the compound patent expires. The IL-4/IL-13 inhibitor accounted for 40% of Sanofi's Q1 sales, per company disclosure, making secondary patent estate strategies a material financial priority. The company's formulation, dosing, and indication-specific patents likely form the basis of its litigation posture. Biosimilar manufacturers including Coherus and Sandoz will calibrate launch timing based on Sanofi's patent strength, with settlement negotiations typically beginning 18-24 months before compound patent expiry.

Competitive implications: Biosimilar developers face 2029-2030 launch planning decisions based on Sanofi's litigation aggressiveness and secondary patent validity. Early settlement with one manufacturer could establish pricing benchmarks affecting subsequent deals, as seen in Humira biosimilar negotiations. Eli Lilly's lebrikizumab and AbbVie's Rinvoq compete in overlapping inflammatory indications, gaining runway if biosimilar entry compresses Dupixent pricing or accelerates share loss. Generic manufacturers with complex biologics experience, including Sandoz and Fresenius Kabi, hold advantages in navigating multi-patent litigation.

Key risks: If Sanofi's secondary patents prove weaker than anticipated, biosimilar entry could occur closer to 2031 than the 2033-2034 timeline the company likely targets. Indication-specific patent gaps could enable biosimilars in certain indications while Sanofi retains exclusivity in others, fragmenting market dynamics.

Tolebrutinib EU-US Split Sets BTK Inhibitor Precedent — Sanofi Gains European Foothold Despite FDA Safety Rejection

Sanofi's tolebrutinib received positive CHMP opinion for secondary progressive MS despite FDA's December complete response letter based on safety concerns, creating a transatlantic regulatory divergence in CNS-penetrant BTK inhibitors. The European recommendation covers only secondary progressive MS patients with active disease, a narrower label than Sanofi sought. Endpoints News reported the CHMP opinion on April 24, 2026. If European Commission approval follows, Sanofi will commercialize ex-US while navigating potential U.S. resubmission requirements. Roche disclosed that deaths from infections, diabetes complications, and an accident drove mortality imbalances in fenebrutinib's Phase 3 relapsing MS trials, per Fierce Biotech, intensifying class-wide safety scrutiny.

Competitive implications: Novartis's Kesimpta and Roche's Ocrevus face new oral BTK competition in Europe but retain uncontested U.S. positioning unless Sanofi resolves FDA concerns. Fenebrutinib's mortality data affects both Roche's own MS program and the broader BTK class perception among prescribers and regulators. Merck KGaA's evobrutinib discontinuation after Phase 3 failure leaves tolebrutinib and fenebrutinib as the only remaining BTK inhibitors in advanced MS development, narrowing the competitive field. If tolebrutinib gains European approval, it establishes the first oral therapy precedent in progressive MS, raising patient and physician expectations that could pressure injectable competitors.

Key risks: European Commission could reject CHMP's positive opinion if safety concerns emerge during final review. FDA resubmission success depends on Sanofi demonstrating that safety issues identified in the CRL can be managed through labeling, risk mitigation, or additional data—a multi-year process with uncertain outcome.

Oral GLP-1 Launch Dynamics Tilt Toward Novo as Foundayo Trails Initial Expectations

Eli Lilly's shares declined as early prescription data for Foundayo, its oral GLP-1 agonist for obesity, trailed Novo Nordisk's oral Wegovy launch trajectory, per Fierce Pharma's inaugural weekly tracking series using IQVIA dispensing data. Novo Nordisk's stock climbed on the comparative dynamic, signaling investor sensitivity to oral GLP-1 commercial uptake in a category where injectable formulations generated tens of billions in 2025 sales. The divergence suggests Foundayo faces steeper commercial headwinds than anticipated, though launch windows remain narrow for definitive assessment. Fierce Pharma will provide ongoing weekly prescription tracking for both products.

Competitive implications: Novo Nordisk gains first-mover advantage in oral GLP-1 obesity positioning while Lilly faces investor skepticism about Foundayo's commercial trajectory. Both companies navigate injectable-to-oral cannibalization questions and payer negotiations around tiering and prior authorization. Amgen's MariTide in development could benefit if early oral GLP-1 launches demonstrate tolerability or adherence challenges, validating alternative mechanisms or dosing approaches. Slower oral uptake extends the commercial runway for injectable franchises including Lilly's Zepbound and Novo's Wegovy.

Key risks: Early prescription data may not reflect final market positioning if payer coverage expands or physician experience improves tolerability management. Comparative effectiveness data between oral and injectable formulations remains limited, creating uncertainty around long-term market share dynamics.

REGULATORY & APPROVALS

• AbbVie received a manufacturing-based CRL for its developmental neurotoxin, delaying succession planning for the $6.4B Botox franchise (combined therapeutic and cosmetic 2025 net revenues per AbbVie FY2025 results) as Revance's Daxxify and Evolus' Jeuveau gain aesthetics runway and Ipsen and Merz retain therapeutic share.
• Compass Pathways, Usona Institute, and Transcend Therapeutics received national priority vouchers for psychedelic treatments under a pilot program that accelerates review timelines, compressing time-to-market versus Cybin, Mind Medicine, and Beckley Psytech facing standard review.
• Regeneron secured FDA approval for Otarmeni, the first gene therapy for inherited hearing loss, establishing category precedent in a segment with no existing FDA-approved competitors. The company will provide treatment at no cost to U.S. patients.
• An unnamed pharma company filed a citizen petition challenging FDA's batch release of complete response letters, seeking tighter controls that could reduce competitive intelligence available through CRL disclosures of manufacturing, clinical, or formulation deficiencies.

CLINICAL DATA

• Novartis terminated two Phase 3 trials for abelacimab after the monthly subcutaneous anticoagulant failed to outperform Bristol Myers Squibb and Pfizer's Eliquis in a pivotal study, validating oral DOAC dominance in atrial fibrillation and VTE prevention.
• Merck disclosed initial clinical data for its PD-1xVEGF bispecific antibody combining checkpoint inhibition with anti-angiogenic activity, competing against Roche's Tecentriq plus Avastin regimen and Bristol Myers Squibb's Opdivo-based combinations.

DEALS & PARTNERSHIPS

• Merck entered a $1 billion AI partnership with Google Cloud, positioning the tech giant alongside Microsoft and AWS in pharma AI infrastructure as competitors including Sanofi and Roche pursue parallel investments.
• The Trump administration completed 17 voluntary drug pricing agreements with Regeneron as final signatory, though enforcement mechanisms and specific pricing concessions remain undisclosed, per STAT.
• Amneal Pharmaceuticals is acquiring a biosimilar company for $375 million upfront, entering a market crowded with specialty manufacturers and Big Pharma entrants competing on interchangeability designations and supply chain integration.
• The Trump administration negotiated a tariff agreement with the UK tying trade concessions to pharmaceutical pricing commitments, establishing potential precedent for bilateral frameworks affecting companies with significant UK and European revenue exposure.

BUSINESS & FINANCE

• AbbVie committed $1.4 billion to a 185-acre Durham, NC manufacturing campus for small-volume parenterals including vials and prefilled syringes, with construction beginning in 2026 and completion targeted for late 2028, per AbbVie press release.
• Roche reported Q1 sales below Wall Street estimates due to Swiss franc appreciation and mixed product performance, per CNBC, while executives projected over $9 billion in combined annual sales for giredestrant and obesity programs per company guidance.
• Pfizer Chief Strategy and Innovation Officer Andrew Baum stepped down from his operational role but will remain a senior strategic advisor to CEO Albert Bourla, reflecting continued organizational adjustment following COVID-era expansion.
• Eli Lilly's $7 billion Kelonia acquisition, following similar deals by Sanofi and Novartis, has sharply narrowed the pool of available in vivo CAR-T targets, with PitchBook analyst Ben Zercher expecting dealmaking to slow due to limited remaining candidates.

WHAT TO WATCH NEXT

Giredestrant Phase III Readouts Through 2026 — Roche's $15B Peak Sales Case on Trial

Roche CEO Thomas Schinecker projected giredestrant could exceed Herceptin's peak sales (approximately $7 billion annually at its 2018 peak per Roche annual reporting) despite the oral SERD's January 2026 failure in first-line HR+/HER2- metastatic breast cancer, pinning projections on second-line and adjuvant readouts expected through 2026 per company guidance. Success would position giredestrant against AstraZeneca's Truqap and Eli Lilly's Verzenio in second-line settings. Failure in remaining indications would eliminate the blockbuster thesis and validate IV SERD and CDK4/6 inhibitor dominance.

Sanofi CEO Transition and R&D Portfolio Review — Immunology and Oncology Priorities Under Reassessment

Sanofi's incoming CEO is reassessing research portfolio priorities amid competitive pressure in immunology and oncology, per STAT, with CFO François-Xavier Roger acknowledging 'a certain number of setbacks' in R&D per The Markets Daily. The review could yield portfolio pruning, therapeutic area pivots, or M&A repositioning. Competitors with overlapping assets may see partnership opportunities if Sanofi divests programs, while rivals in targeted areas could gain share during transition. The outcome will clarify whether Sanofi doubles down on existing franchises or shifts modality focus.

Biosimilar Manufacturers Calibrate Dupixent Launch Timing — Key Negotiation Window Approaches

Watch for biosimilar filing activity from Coherus, Sandoz, and Fresenius Kabi as the 2029–2030 settlement negotiation window opens ahead of Dupixent's March 2031 compound patent expiry. Early settlement with one manufacturer could establish pricing benchmarks affecting subsequent deals, as seen in Humira biosimilar negotiations. Indication-specific patent gaps may enable selective market entry—biosimilars could launch in certain indications while Sanofi retains exclusivity in others, fragmenting competitive dynamics.